Preformulation design of PLGA particulate system for multi-day drug delivery of the antidepressant mirtazapine-Reference-Cited by-同舟云学术

Preformulation design of PLGA particulate system for multi-day drug delivery of the antidepressant mirtazapine

Published:2021 Issue:6 Volume:70 Page:210-219
ISSN:1210-7816
Container-title:Česká a slovenská farmacie
language:
Short-container-title:CSF

Author:

Holická Martina,Muselík Jan,Kejdušová Martina,Pavelková Miroslava,Kubová Kateřina,Doležel Petr,Vetchý David,Košťál Vratislav,Vysloužil Jakub,Mašek Josef

Abstract

In this experimental study, the biodegradable polylactide-co-glycolide (PLGA) microparticles (MP) loaded with the insoluble antidepressant mirtazapine were prepared by the simple o/w solvent evaporation method. The formation involved intrinsic variables,

Publisher

Masaryk University Press

Subject

Pharmaceutical Science

Reference30 articles.

1. Okubo M., Murayama N., Miura J., Chiba Y., Yamazaki H. Effects of cytochrome P450 2D6 and 3A5 genotypes and possible coadministered medicines on the metabolic clearance of antidepressant mirtazapine in Japanese patients. Biochem. Pharmacol. 2015; 93, 104-109.

2. Anttila S. A., Leinonen E. V. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001; 7, 249-264.

3. Kasper S., Praschak-Rieder N., Tauscher J., Wolf R. A risk-benefit assessment of mirtazapine in the treatment of depression. Drug Saf. 1997; 17, 251-264.

4. Verster J. C., van de Loo A. J. A. E., Roth T. Mirtazapine as positive control drug in studies examining the effects of antidepressants on driving ability. Eur. J. Pharmacol. 2015; 753, 252-256.

5. Timmer C. J., Sitsen J. M., Delbressine L. P. Clinical pharmacokinetics of mirtazapine. Clin. Pharmacokinet. 2000; 38, 461-474.